• Aconitase Activity Colorimetric Assay Kit: Sensitive TCA Cyc

  2026-06-15

  The Aconitase Activity Colorimetric Assay Kit enables rapid, quantitative measurement of aconitase enzyme activity, a key biomarker for mitochondrial function and oxidative damage. This kit provides high-throughput, colorimetric detection based on the iron-sulfur protein aconitase, supporting advanced TCA cycle enzyme assays in biomedical research.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitio

  2026-06-15

  Clasto-Lactacystin β-lactone stands out as an advanced, irreversible proteasome inhibitor, driving robust and reproducible ubiquitin-proteasome pathway assays. Its heightened selectivity transforms research in cancer, neurodegenerative, and viral immunology models, opening avenues for targeted mechanistic dissection.

• Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Stu

  2026-06-14

  Harness Dehydroabietic acid’s unique dual PPAR-α/γ agonist activity to unlock new approaches in lipid metabolism regulation and insulin sensitivity improvement. Learn optimized protocols, troubleshooting tips, and how this APExBIO molecule integrates with advanced metabolic disorder research including CRISPR-based workflows.

• Propranolol Reprograms Burn-Induced Metabolic Pathways

  2026-06-13

  This phase II randomized controlled trial demonstrates that propranolol, a nonselective beta-blocker, normalizes metabolomic and lipidomic profiles in severely burned patients by targeting key metabolic pathways in adipose tissue. The findings provide mechanistic insight into how propranolol mitigates hypermetabolic stress, revealing potential translational strategies for metabolic modulation after severe injury.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-12

  Schwartz (2022) introduces a quantitative approach to disentangle proliferative arrest and cell death in cancer drug assays, revealing that most agents induce both effects with distinct timing and magnitude. This framework improves the interpretation and design of preclinical studies for anti-proliferative and apoptosis-inducing compounds.

• U0126-EtOH: Precision MEK1/2 Inhibition for Redox Signaling

  2026-06-12

  Explore how U0126-EtOH, a potent MEK1/2 inhibitor, advances oxidative stress and signaling pathway research with unparalleled selectivity. This article uniquely connects mechanistic insights to practical assay decisions in neuronal and inflammatory models.

• Atrial Natriuretic Peptide in Cardiovascular Research: Advan

  2026-06-11

  Unlock the full experimental potential of Atrial Natriuretic Peptide (ANP) in cardiovascular and metabolic studies. This article delivers applied workflows, protocol refinements, and troubleshooting strategies that leverage APExBIO’s high-purity rat ANP to advance blood pressure, natriuresis, and adipose metabolism research.

• Probenecid (4-(dipropylsulfamoyl)benzoic acid): Beyond MRP I

  2026-06-11

  Explore Probenecid's nuanced role as a multitarget biochemical inhibitor, including its impact on multidrug resistance and neuroprotection. This in-depth analysis reveals unique systems biology insights not found in other sources.

• FITC Goat Anti-Rabbit IgG (H+L) Antibody for Superior Biomar

  2026-06-10

  Leverage the FITC Goat Anti-Rabbit IgG (H+L) Antibody for unprecedented sensitivity in immunofluorescence and flow cytometry. This reagent streamlines quantitative biomarker discovery and troubleshooting in translational research, ensuring robust, reproducible results.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1 for Targ

  2026-06-10

  PYR-41, a potent inhibitor of Ubiquitin-Activating Enzyme E1 from APExBIO, empowers researchers to dissect protein homeostasis and immune signaling in both cell and animal models. Its unique inhibition profile enables precise modulation of the ubiquitin-proteasome system and NF-κB pathway, making it indispensable for studies in inflammation, apoptosis, and cancer immunology.

• GW4064: Advanced FXR Agonist Insights for Fibrosis & Metabol

  2026-06-09

  Explore how GW4064, a potent non-steroidal FXR agonist, empowers metabolic and fibrosis research through novel FXR/TLR4 pathway modulation. This article delivers protocol guidance and unique assay insights, surpassing current content with a focus on mechanistic clarity and experimental application.

• NDRG2-Driven DRP1 Phosphorylation Promotes Pulmonary Hyperte

  2026-06-09

  This study reveals that NDRG2 accelerates pulmonary hypertension (PH) by promoting DRP1 phosphorylation, leading to excessive mitochondrial fission and vascular remodeling. These insights highlight the NDRG2-DRP1 axis as a promising therapeutic target for PH and demonstrate the value of precise cell proliferation assessment in vascular research.

• Deep Learning Detects Cardiotoxicity in iPSC-CM Screens

  2026-06-08

  Grafton et al. introduce a deep learning approach to rapidly identify cardiotoxicity in high-content screens using human iPSC-derived cardiomyocytes. This innovation enables scalable, phenotypic drug safety assessment at early stages of drug discovery, with implications for improving predictive cardiac electrophysiology research.

• Aconitase Activity Colorimetric Assay Kit: Precision in TCA

  2026-06-08

  The Aconitase Activity Colorimetric Assay Kit enables rapid, quantitative detection of iron-sulfur protein aconitase activity, serving as a sensitive marker for oxidative damage and mitochondrial function. This kit offers precise colorimetric readouts for citrate-to-isocitrate isomerization, making it ideal for high-throughput TCA cycle enzyme assays and immunometabolism research.

• MLN4924 HCl Salt: Neddylation Pathway Inhibition in Viral Im

  2026-06-07

  Explore how MLN4924 HCl salt, a potent NEDD8-activating enzyme inhibitor, enables advanced investigation of viral modulation of necroptosis and inflammation. This article uncovers new research frontiers for neddylation pathway inhibition in immune signaling and viral-host interactions.

16599 records 1/1107 page Next 12345 下5页 Last page